Verification evidence is still being completed.
PDF / print export
Engimmune Therapeutics
Allschwil, Switzerland
- Verified lead
- Lars Nieba
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering
- Review cycle
- 24 April 2026
- Full address
- Allschwil, Basel area, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- PR Newswire release confirming Lars Nieba as Chief Executive Officer of Engimmune Therapeutics.
- Editorial note
- Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering
ETH Zurich spin-off, Novo Holdings investment, BaseLaunch portfolio recognition
Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Allschwil, Switzerland
Engimmune Therapeutics
Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering · Preclinical TCR therapeutic development
Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
- Lead
- Lars Nieba (verified ↗)
- Address
- Allschwil, Basel area, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical TCR therapeutic development
- Capabilities
- Soluble TCR Discovery and Engineering · Protein Engineering with Machine Learning · Multi-Specific Therapeutic Design
- Founded
- 2019
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Lars Nieba
Chief Executive Officer
Full addressAllschwil, Basel area, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
BaseLaunch success-story profile placing Engimmune in the Allschwil Basel area.
Open sourcePreclinical TCR therapeutic development
Allschwil, Switzerland. Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for future clinical development
ETH Zurich spin-off, Novo Holdings investment, BaseLaunch portfolio recognition
Soluble T-Cell Receptor Therapeutics, Solid Tumour Oncology, and Multi-Specific TCR Engineering
Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours.
Editorial note
Engimmune Therapeutics is an ETH Zurich spin-off from the Reddy group combining protein engineering with machine learning for TCR discovery, with a named CEO, Novo Holdings investment, and BaseLaunch success-story recognition.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Soluble TCR Discovery and Engineering
Protein Engineering with Machine Learning
Multi-Specific Therapeutic Design
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
TCR discovery platform
Protein engineering workflow
Machine learning pipelines
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Engimmune Therapeutics located?
- Engimmune Therapeutics operates from Allschwil, Basel area, Switzerland, Allschwil, Switzerland.
- Who runs Engimmune Therapeutics?
- Engimmune Therapeutics is led by Lars Nieba, Chief Executive Officer. Verified 24 Apr 2026.
- What does Engimmune Therapeutics do?
- Allschwil ETH Zurich spin-off with named CEO, 15.5 million CHF seed financing, Novo Holdings investment, and a soluble TCR therapeutic pipeline for solid tumours. Core capabilities: Soluble TCR Discovery and Engineering, Protein Engineering with Machine Learning, Multi-Specific Therapeutic Design.
Editorial context
Related technical briefs
Briefs that name Allschwil as a covered market or city.